SAGE Therapeutics Inc (NASDAQ:SAGE) Stock Position Cut by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lessened its stake in SAGE Therapeutics Inc (NASDAQ:SAGE) by 95.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,031 shares of the biopharmaceutical company’s stock after selling 20,920 shares during the period. DekaBank Deutsche Girozentrale’s holdings in SAGE Therapeutics were worth $75,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in SAGE. Ikarian Capital LLC bought a new position in SAGE Therapeutics in the 4th quarter valued at about $9,601,000. State Street Corp grew its position in SAGE Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 1,039,599 shares of the biopharmaceutical company’s stock valued at $145,845,000 after buying an additional 84,138 shares in the last quarter. BlackRock Inc. boosted its position in shares of SAGE Therapeutics by 2.8% during the 2nd quarter. BlackRock Inc. now owns 2,748,713 shares of the biopharmaceutical company’s stock valued at $503,261,000 after purchasing an additional 75,246 shares in the last quarter. TimesSquare Capital Management LLC boosted its position in shares of SAGE Therapeutics by 12.1% during the 3rd quarter. TimesSquare Capital Management LLC now owns 570,500 shares of the biopharmaceutical company’s stock valued at $80,035,000 after purchasing an additional 61,500 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. boosted its position in shares of SAGE Therapeutics by 40.7% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 136,459 shares of the biopharmaceutical company’s stock valued at $21,704,000 after purchasing an additional 39,447 shares in the last quarter.

SAGE stock opened at $68.61 on Wednesday. The company has a current ratio of 12.67, a quick ratio of 12.67 and a debt-to-equity ratio of 0.03. SAGE Therapeutics Inc has a one year low of $56.50 and a one year high of $193.56. The firm has a market capitalization of $3.56 billion, a PE ratio of -5.08 and a beta of 2.43. The firm has a 50-day moving average of $71.21 and a two-hundred day moving average of $121.75.

In other news, insider Albert Robichaud acquired 25,000 shares of SAGE Therapeutics stock in a transaction on Monday, December 9th. The stock was bought at an average cost of $64.16 per share, with a total value of $1,604,000.00. Following the completion of the purchase, the insider now owns 102,592 shares of the company’s stock, valued at $6,582,302.72. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jeffrey M. Jonas acquired 7,500 shares of SAGE Therapeutics stock in a transaction on Monday, December 9th. The shares were purchased at an average cost of $64.20 per share, with a total value of $481,500.00. Following the completion of the purchase, the chief executive officer now directly owns 54,530 shares of the company’s stock, valued at approximately $3,500,826. The disclosure for this purchase can be found here. 4.60% of the stock is currently owned by corporate insiders.

Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. reduced their price objective on shares of SAGE Therapeutics from $200.00 to $105.00 and set an “overweight” rating for the company in a research report on Friday, December 6th. Morgan Stanley reduced their price objective on shares of SAGE Therapeutics from $217.00 to $125.00 and set an “overweight” rating for the company in a research report on Friday, December 6th. BMO Capital Markets restated an “outperform” rating and set a $92.00 price objective on shares of SAGE Therapeutics in a research report on Friday, December 6th. Royal Bank of Canada reduced their price objective on shares of SAGE Therapeutics from $190.00 to $100.00 and set an “outperform” rating for the company in a research report on Friday, December 6th. Finally, BidaskClub lowered shares of SAGE Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $123.78.

SAGE Therapeutics Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

See Also: Options Trading – What is a Straddle?

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit